Phase 1 Iontophoretic Delivery of Dexamethasone for Tx of Anterior Scleritis |
Nisha Acharya, MD |
Eye Disease and Blindness, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial |
Nisha Acharya, MD |
Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial |
Nisha Acharya, MD |
Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial |
Nisha Acharya, MD |
Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
Iontophoresis Delivery of Dexamethason Phosphate for Non-Infectious, No-Necrotizing Anterior Scieritis, Phase I Dose-Varying Study |
Nisha Acharya, MD |
Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
Replication fidelity mutants as attenuated poliovirus seeds for IPV production |
Raul Andino-Pavlovsky, PhD |
Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
RAPID: Ebola virus population structure, genetic diversity and evolution |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
2 year joint fellowship program in Clinical Pharmacy with Actelion |
Francesca Aweeka, PharmD |
Drug and Diagnostics Development, Pharmacology and Drug Treatment, Residencies, Fellowships, and Postdoctoral Training |
|
|
Quality Assurance/Quality Control Program |
Francesca Aweeka, PharmD |
Pharmacology and Drug Treatment |
|
|
LOC-IMPAACT Leadership Group |
Francesca Aweeka, PharmD |
HIV/AIDS, Tuberculosis, Drug and Diagnostics Development, Pharmacology and Drug Treatment, Women's Health, Pediatrics, Newborn and Infant Health, Systematic Reviews and Guideline Development |
|
|
Pharmacogenomics of Bronchodilator Response in Minority Children with Asthma |
Esteban Burchard, MD, MPH |
Chronic Respiratory Disease, Genetics, Pharmacology and Drug Treatment, Pediatrics |
|
|
Clinical Pharmacology, Drug Action and Pharmacogenetics |
Esteban Burchard, MD, MPH |
Pharmacology and Drug Treatment, Residencies, Fellowships, and Postdoctoral Training |
|
|
Protocol Development for a Phase 2 Study Evaluating the Safety and Feasibility of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Phase 2 Study, Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
A Phase 2, Randomized, Open-Labeled Study on the Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Ceftobiprole vs. Daptomycin and Linezolid for Treatment of Experimental Staph. aureus Endocarditis in Rabbits |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Tetrezolid vs. Daptomycin and Vancomycin for Treatment of Experimental Staphylococcus aureus |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
HPTN 084 Qualitative Substudy Funding |
Zvavahera Chirenje, MD, FRCOG |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
IMPAACT Yr 08 P1077 CTU MOU #2 - St. Mary's |
Zvavahera Chirenje, MD, FRCOG |
HIV/AIDS, Pharmacology and Drug Treatment, Women's Health, Labor and Delivery, Family Planning, Newborn and Infant Health, Risk Reduction and Prevention |
|
|
University of California Global Health Institute Program for Fellows and Scholars |
Craig Cohen, MD, MPH |
Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), HIV/AIDS, Opportunistic Infection, Tuberculosis, Malaria, Noncommunicable and/or Chronic Disease, Surgery and Anesthesia, Cancer/Oncology, Cardiovascular Disease, Chronic Respiratory Disease, Diabetes, Occupational and Environmental Disease, Diet, Exercise, and Obesity, Malnutrition, Micronutrients, Food Insecurity, Eye Disease and Blindness, Oral Health, Drug and Diagnostics Development, Immunology, Genetics, Pharmacology and Drug Treatment, Neurology and Mental Health, Dementia and Cognitive Impairment, Trauma and PTSD, Women's Health, Aging, Labor and Delivery, Family Planning, Pediatrics, Newborn and Infant Health, Adolescent Health, Health Economics and Effectiveness, Access or Barriers to Care, Immigration and Migration, Stigma and Discrimination, Smoking and Tobacco, Policy and Standards of Care, Systematic Reviews and Guideline Development, Epidemiology and Surveillance, Triangulation, Global Strategic Information, Implementation and Behavioral Science, Engagement in Care, Substance Abuse, Treatment Adherence, Health Systems Strengthening, Risk Reduction and Prevention, Residencies, Fellowships, and Postdoctoral Training |
|
|
Targeting host autophagy for treating Mtb infections and synergizing with antibiotics in vivo |
|
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Pharmacology and Drug Treatment |
|
|
Enfuvirtide Intensification for Multi-Drug Resistant HIV |
Steven Deeks, MD |
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
San Francisco National Clinical Trial Center, ESPIRIT |
Steven Deeks, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Short-Term Disulfiram Administration to Reverse Latent HIV Infection |
Steven Deeks, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Interruption of Enfuvirtide in Patients Experiencing an Incomplete Virologic Response to Enfuvirtide-Based Combination Antiretroviral Regimen |
Steven Deeks, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Immediate Salvage Therapy w/ Combination ART plus T-20 vs. A 16 Week Structured Treatment Interruption Followed by Combination Therapy plus T-20 |
Steven Deeks, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Enfuvirtide Treatment Intensification in Patients with Multi-Drug Resistant HIV |
Steven Deeks, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
AIDS Clinical Trials Network (ACTG)-Deeks (Co-Vice Chair) A5296 |
Steven Deeks, MD |
HIV/AIDS, Noncommunicable and/or Chronic Disease, Pharmacology and Drug Treatment |
|
|
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation |
Steven Deeks, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Assessing Antiretroviral Exposure in Diverse Populations |
Monica Gandhi, MD, MPH |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Early Mortality in HIV-Infected Patients Starting Antiretroviral Therapy in Africa |
|
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Role of ABCG2 in the disposition and anti-hyperuricemic effects of allopurinol |
|
Pharmacology and Drug Treatment |
|
|
Systems Pharmacology Approaches to Understanding Drug Induced Weight Gain |
|
Pharmacology and Drug Treatment |
|
|
Tenofovir Kidney Toxicity Study |
|
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
P.falciparum infection dynamics and transmission to inform elimination (INDIE) |
Bryan Greenhouse, MD |
Malaria, Pharmacology and Drug Treatment |
|
|
Oral Drug Treatment for Enhanced Immune Control over HIV Replication |
|
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
ACE-Inhibitors to Decrease Lymphoid Fibrosis and the Size of the Latent Reservoir in Antiretroviral-Treated, HIV-infected Patients: A Randomized, Placebo-Controlled Study |
|
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Study of Three NNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (ACTG A5257) |
Diane Havlir, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects (ATCG A5262) |
Diane Havlir, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
SFBay CTU |
Diane Havlir, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
ADS-TCAD-P0206: TCAD Oral for Treatment of Influenza A |
Diane Havlir, MD |
Infectious Disease, HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
Novel Strategies to Prevent Malaria and Improve Maternal-Child Health in Africa (PROMOTE) |
Diane Havlir, MD |
HIV/AIDS, Malaria, Pharmacology and Drug Treatment, Women's Health, Pediatrics, Newborn and Infant Health |
|
|
Task Order # 9: Supplement to SSS A5272 |
Diane Havlir, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Task Order Supplement to A5267 |
Diane Havlir, MD |
HIV/AIDS, Tuberculosis, Pharmacology and Drug Treatment |
|
|
Effect of low dose methotrexate on endothelial function and inflammation in HIV - A5314 |
Diane Havlir, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Task Order A5303: Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naive Patients Infected with R5-Tropic HIV-1 |
Diane Havlir, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection |
|
HIV/AIDS, Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-Sulfamethoxazole for Treatment of Acute Pneumocystis jiroveci Pneumnia (PCP) in Patients with HIV/AIDS |
Laurence Huang, MD |
HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts |
Vivek Jain, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
HIV Emergence of Drug Resistance |
|
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
AI452-020-0092: Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or Re |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
GS-US-367-1172: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Steroids and Cross-linking for Ulcer Treatment (SCUT II) |
Thomas Lietman, MD |
Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
AVENIR: Assessing the impact of azithromycin on child mortality in Niger |
Thomas Lietman, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Pharmacology and Drug Treatment, Pediatrics, Newborn and Infant Health, Health Economics and Effectiveness |
|
|
The Steroids for Corneal Ulcers Trial |
Thomas Lietman, MD |
Infectious Disease, Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
What is the Appropriate Frequency and Duration of Mass Azithromycin |
Thomas Lietman, MD |
Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
Research to Programs for Trachoma Elimination |
Thomas Lietman, MD |
Infectious Disease, Eye Disease and Blindness, Pharmacology and Drug Treatment, Epidemiology and Surveillance |
|
|
Mycotic Ulcer Treatment Trial |
Thomas Lietman, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
TANA II |
Thomas Lietman, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment, Epidemiology and Surveillance |
|
|
P-S RPB - Assessing Corneal Ulcer Prevention with a Community-Randomized Trial |
Thomas Lietman, MD |
Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
Eliminating Trachoma with Repeat Mass Drug Treatment |
Thomas Lietman, MD |
Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
ASN100-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Gilead GS-US-236-0102 |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
M14-730 (EXPEDITION-2): A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Co |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
MK-3682B-037-00A: Phase 3 Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of a Novel CCR5 Antagonist, UK427,857, for the Treatment of Antiretroviral-Experienced HIV-1-Infected Subjects |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
A phase III trial to investigate the efficacy, tolerability & safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects w/ limited to no treatment options |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Tibotec TMC125-C214: Early Access of TMC125 in Combination with Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment 0ptions |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Tobira 652-2-202 Pre-Clinical Trial Cost Agreement |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
GSK_201585: Phase III, randomized, multicenter, parallel-group, non inferiority, open-label study evaluating the efficacy, safety, & tolerability of switching to long-acting cabotegravir plus long acting rilpivirine from current INI,NNRTI, or PI-based ART |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 and ABT-333 Coadministered with Ribavirin in Adults with Genotype 1 Chronic HCV and HIV |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Entecavir Intensification for HIV-HBV Coinfected subjects with persistent HBV viremia |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Pfizer A4001027: Observational Phase Extension |
Anne Luetkemeyer, MD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Evaluation of technetium Tc 99m tilmanocept (Lymphoseek) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage from KS Lesions by SPECT and SPECT/CT Imaging |
Toby Maurer, MD |
HIV/AIDS, Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Role of Buprenorphine in Improving Clinical Care in Opioid Addiction and HIV |
|
HIV/AIDS, Pharmacology and Drug Treatment, Substance Abuse |
|
|
High Throughput Assay for Screening Compounds Against T. Brucei |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Host Protein Degradation by Schistosome Parasites |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Optimization of Cysteine Protease Inhibitors Targeting Trypanosoma Brucei |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Targeting Cysteine Proteases--Antiparasitic Chemotherapy |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Transcriptional Responses of Parasite and Host during Intestinal Colonization and Invasion by Entamoeba histolytica |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Misoprostol for Prevention or Early Treatment |
Suellen Miller, PhD, CNM, MHA |
Pharmacology and Drug Treatment, Labor and Delivery |
|
|
Tuberculosis Trials Consortium (TBTC) |
Payam Nahid, MD, MPH |
Tuberculosis, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
The Impact of Anogenital Human Papillomavirus in the Transmission of HIV in Urban Brazil: Phase II Study |
Joel Palefsky, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Thai Red Cross S&S, HPV TA008 |
Joel Palefsky, MD |
Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Pharmacogenomics of Antimalarial Drugs |
Sunil Parikh, MD, MPH |
Malaria, Genetics, Pharmacology and Drug Treatment |
|
|
Vision to Discover New Treatments for Parkinson's and Other Neurodegenerative Diseases |
|
Pharmacology and Drug Treatment, Neurology and Mental Health |
|
|
Expanded Access to MGAWN1 in Subjects with Suspected West Nile Neuroinvasive Disease; Substantial Exposure, or Infection and a Compromised Immune System |
Jeffrey Ralph, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Pharmacology and Drug Treatment |
|
|
Medical Pharmacy Consultation Team |
E. Michael Reyes, MD, MPH |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Medical Pharmacy Consultation Team |
E. Michael Reyes, MD, MPH |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Pharmacodynamics of Antimalarial Chemoprevention |
Philip J. Rosenthal, MD |
Malaria, Pharmacology and Drug Treatment |
|
|
A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination with Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus |
|
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment, Pediatrics |
|
|
Protocol AI463-189-004: A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) |
|
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infection |
|
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Protocol Development Co-Chair for Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK 1349572, a novel integrase inhibitor, in combination regimens in HIV-1 Infected Infants, Children & Adolescents |
Theodore Ruel, MD |
HIV/AIDS, Pharmacology and Drug Treatment, Pediatrics, Adolescent Health |
|
|
Quality of Sleep in HIV-Infection: Association with Treatment and Adherence |
Parya Saberi, PharmD |
HIV/AIDS, Pharmacology and Drug Treatment, Treatment Adherence |
|
|
Genome-Wide Association Study to Examine Genes Associated with An Increased Risk of Febrile Seizure in Children Following Measles-Containing Vaccines |
Mark Seielstad, PhD |
Infectious Disease, Transfusion Medicine, Immunology, Pharmacology and Drug Treatment, Pediatrics, Epidemiology and Surveillance |
|
|
Tenofovir in Pregnancy (TIP) Study |
|
HIV/AIDS, Pharmacology and Drug Treatment, Women's Health, Newborn and Infant Health |
|
|
Preventing the Neonatal Narcotic Abstinence Syndrome (NAS) |
Juan Vargas, MD |
Pharmacology and Drug Treatment, Newborn and Infant Health, Substance Abuse |
|
|
UCSF-GIVI Center for AIDS Research (CFAR) |
Paul Volberding, MD |
HIV/AIDS, Tuberculosis, Malaria, Cancer/Oncology, Cardiovascular Disease, Drug and Diagnostics Development, Immunology, Pharmacology and Drug Treatment, Neurology and Mental Health, Trauma and PTSD, Women's Health, Pediatrics, Implementation and Behavioral Science, Training and Capacity Building, Training International Scholars and Clinicians |
|
|
CHRP Disparities Initiative: UCSF CFAR Conference Award |
Paul Volberding, MD |
HIV/AIDS, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Financial Impact of the Current and Alternative Pricing Practices for Compounded, Co-packaged, and Over-the-Counter drugs and Medical Foods within the California Workers' Compensation System: Non-Formulary Impact if Pharmacy or Physician Dispensed |
Leslie Wilson, PhD, MS |
Pharmacology and Drug Treatment, Health Economics and Effectiveness, Access or Barriers to Care |
|
|
Navigating the Scientific Evidence to Ensure Prevention |
Tracey Woodruff, PhD, MPH |
Occupational and Environmental Disease, Pharmacology and Drug Treatment, Systematic Reviews and Guideline Development, Epidemiology and Surveillance |
|
|
Clinical Pharmacology, Drug Action and Pharmacogenetics |
Neal Benowitz, MD |
Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
A Pilot Study of FOLFOX in Combination with Bevacizumab in Patients with Advanced Neuroendocrine Tumors |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Improving Medicines Use for Noncommunicable Diseases in Low Resource Settings |
Lisa Bero, PhD |
Pharmacology and Drug Treatment, Access or Barriers to Care, Policy and Standards of Care, Systematic Reviews and Guideline Development |
|
|
Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients with High Grade Glioma |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
JBAL: A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Protocol # ADMA-001: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial Evaluating the Safety and Efficacy of RI-001 in Medically Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV |
|
HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
Efficacy and Safety of Eraxis/Ecalta (Anidulafungin) Compared to Cancidas (Caspofungin) in Patients with Candida Deep Tissue Infection: A Phase 4 Study |
|
Infectious Disease, HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
WSA-CS-003: Open Label Study of Isavuconazole in the Treatment of Patients with Aspergillosis and Renal Impairment or of Patients with Invasive Fungal Disease Caused by Rare Molds, Yeasts or Dimorphic Fungi |
|
Infectious Disease, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants |
|
Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
Phase IV Open-Label, Non-comparative Trial of IV Anidulafungin followed by Oral Azole Therapy for the Treatment of Candidemia and Invasive Candidiasis |
|
HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
A8851009: A Prospective, Randomized Trial Comparing the Efficacy of Anidulafungin and Voriconazole in Combination to that of Voriconazole Alone When Used For Primary Therapy of Proven or Probable Invasive Aspergillosis |
|
Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
Misoprotsol versus Placebo with Laminaria for Cervical Ripening before Late Second Trimester Abortion |
Philip Darney, MD, MS |
Pharmacology and Drug Treatment, Family Planning |
|
|
Phase 3, Randomized, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System (20 Mcg/Day) and Mirena® for Long-Term, Reversible Contraception up to Five Years |
Philip Darney, MD, MS |
Pharmacology and Drug Treatment, Family Planning |
|
|
Multi-center, open-label, uncontrolled study to assess contraceptive efficacy and safety of Mirena during extended use beyond 5 years in women 18 to 35 years of age including a subgroup evaluation of treatment effect on heavy menstrual bleeding |
Philip Darney, MD, MS |
Pharmacology and Drug Treatment, Women's Health, Family Planning |
|
|
Implantable multi-analyte sensors for the continuous monitoring of body chemistries |
Tejal Desai, PhD |
Pharmacology and Drug Treatment |
|
|
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) |
Jacque Duncan, MD |
Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
Statistical methods for clinical trials of novel PrEP agents |
David Glidden, PhD |
HIV/AIDS, Pharmacology and Drug Treatment, Systematic Reviews and Guideline Development |
|
|
Comparison of Pharmacologic Markers of Exposure to HIV Pre-Exposure Prophylaxis |
David Glidden, PhD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
The Use of Nelfinavir During Acute or Early HIV Infection - Safety, Tolerability, Durablilty and Resistance |
|
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Task Order #1 RAMPART Study - Neurological Emergencies Treatment Trials |
|
Pharmacology and Drug Treatment, Neurology and Mental Health |
|
|
Task Order #3: Protect II Study - Neurological Emergencies Treatment Trial |
|
Pharmacology and Drug Treatment, Neurology and Mental Health, Trauma and PTSD |
|
|
Ultrasensitive Monitoring of HIV-1 Drug Resistance Reversion Following Transmission with Drug Resistant Virus |
|
HIV/AIDS, Pharmacology and Drug Treatment, Women's Health, Newborn and Infant Health |
|
|
PAAR4Kids-Pharmacogenomics Research Network |
|
Cancer/Oncology, Genetics, Pharmacology and Drug Treatment |
|
|
Botulinum neurotoxin (BoNT) Collaboration |
|
Occupational and Environmental Disease, Pharmacology and Drug Treatment |
|
|
An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-Daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder |
|
Genetics, Pharmacology and Drug Treatment, Neurology and Mental Health |
|
|
A Phase 4, Randomized, Double-Blind, Multicenter, Parallel-Group, Active-Controlled, Forced-Dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®) with a Placebo Reference Arm, in Adolescents Aged 13-17 Year |
|
Pharmacology and Drug Treatment, Neurology and Mental Health |
|
|
Phase 4, Parallel Group, Active-Controlled, Dose-Optimization Study of SPD489 (Vyvanse) Compared with OROS-MPH (Concerta) with a Placebo Reference Arm, in Adolescents 13-17 with Attention-deficit/Hyperactivity Disorder |
|
Pharmacology and Drug Treatment |
|
|
Phase 1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, A Humanized 1gG1 Antibody in Combination with Bevacizumab with or without Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Malignancies That Are Refractory to All Standard |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Genetic Determinants of Capecitabine Toxicity |
|
Genetics, Pharmacology and Drug Treatment |
|
|
BEACON Study (BrEAst Cancer Outcomes with NKTR-102): Phase 3 Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with Anthracycline, a Taxane and Capecitabine |
|
Cancer/Oncology, Pharmacology and Drug Treatment, Women's Health |
|
|
Nonlinear Mixed Effects Modeling of Rifapentine Pharmacokinetics |
Rada Savic, PhD |
Tuberculosis, Pharmacology and Drug Treatment |
|
|
Development of Rectal Enema As Microbicide (DREAM) |
Rada Savic, PhD |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Mechanism-Based Integrative Pharmacology Model for Tuberculosis |
Rada Savic, PhD |
Tuberculosis, Pharmacology and Drug Treatment |
|
|
Impact of Pregnancy on Tuberculosis |
Rada Savic, PhD |
Tuberculosis, Pharmacology and Drug Treatment, Women's Health, Labor and Delivery, Newborn and Infant Health |
|
|
Identifying Optimal Treatment Strategies for Tuberculosis Treatment |
Rada Savic, PhD |
Tuberculosis, Pharmacology and Drug Treatment |
|
|
A Randomized Controlled Trial Evaluating Locally Administered Gentamicin in the Prevention of Deep Infection after Open Tibial Shaft Fractures in Tanzania |
David Shearer, MD |
Opportunistic Infection, Surgery and Anesthesia, Pharmacology and Drug Treatment |
|
|
A Specific Mechanism for non-specific inhibition |
|
Pharmacology and Drug Treatment |
|
|
Randomized Controlled Trial of 6% Cellulose Sulfate Gel and the Effect on Vaginal HIV Transmission |
Ariane Van der Straten, PhD, MPH |
Sexually Transmitted Infections (STIs), HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Phase III Clinical Trial "Platelet Oriented Inhibition in New Tia" - Drug: Plavix |
|
Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
MAPS: Matrix And Platinum Science, A Prospective, Randomized, Multicenter, Trial Investigating Matrix2 tm and GDC? Coils for the treatment of intracranial saccular aneurysms Trial |
|
Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
Optimizing Management of Transient Ischemic Attacks |
|
Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
SOCRATES - Acute Stroke Or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes |
|
Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
CASTIA Neurological Core Imaging Lab (NCIL) |
|
Cardiovascular Disease, Pharmacology and Drug Treatment, Neurology and Mental Health |
|
|
Antiplatelet Therapy for Ischemic Stroke and Transient Ischemic Attack in U.S. Community Hospitals |
|
Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts (SILCAAT) |
James Kahn, MD, MPH |
HIV/AIDS, Pharmacology and Drug Treatment, Health Economics and Effectiveness |
|
|
Provider Practices in Non-Malarial Fevers: A Pilot Study in Malawi |
Kimberly Baltzell, RN, PhD, MS |
Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Life After Pediatric Sepsis Evaluation, LAPSE |
|
Drug and Diagnostics Development, Pharmacology and Drug Treatment, Pediatrics |
|
|
Development of Regulatory T-Cells for Treatment of Autoimmune Disease |
Jeffrey Bluestone, PhD |
Immunology, Pharmacology and Drug Treatment |
|
|
Biotest Analysis for HCMV Infection in Placentas |
Lenore Pereira, PhD |
Infectious Disease, Pharmacology and Drug Treatment, Women's Health, Newborn and Infant Health |
|
|
Pharmacokinetics and tolerability of adjunctive linezolid for the treatment of tuberculous meningitis |
Felicia Chow, MD |
HIV/AIDS, Tuberculosis, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Selectively targeting delta opioid receptor subtypes to control drinking behavior |
Jennifer Whistler, PhD |
Pharmacology and Drug Treatment, Substance Abuse |
|
|
Therapeutic Effects of Pharmacological Manipulation of Intracellular Nitric Oxide Levels in Cardiovascular Disease |
|
Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
The No One Waits (NOW) Study: Acceptability, feasibility, and effectiveness of a community based on-site point-of-diagnosis HCV treatment study |
Meghan Morris, PhD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Pharmacology and Drug Treatment, Epidemiology and Surveillance |
|
|
Building evidence to support safe radical cure for P. vivax in Lao PDR: operational research in collaboration with UCSF |
Adam Bennett, PhD, MA |
Malaria, Pharmacology and Drug Treatment |
|
|
Pre-CTA A Double-blind, Randomized and Placebo-controlled Study to Evaluate the Safety and Efficacy of T89 in Preventing Acute Mountain Sickness (AMS) During Rapid Ascent |
Jeffrey Sall, PhD, MD |
Occupational and Environmental Disease, Pharmacology and Drug Treatment |
|
|
Consultancy to develop a global demand forecasting for malaria rapid diagnostic tests, artemisinin-based combination therapies and artemisinin |
Colin Boyle, MPP, MBA |
Pharmacology and Drug Treatment, Access or Barriers to Care |
|
|
Can Risedroneate & PTH Reverse Glucocorticoid-Induced Osteoporosis |
Lisa Chen, MD |
Pharmacology and Drug Treatment |
|
|
A phase II study of intravenous T900607-sodium in subject with previously treated ovarian cancer |
Lisa Chen, MD |
Pharmacology and Drug Treatment |
|
|
Study of the Efficacy of Glucosamine/Chondroitin Sulfate in Knee Osteoarthritis - Ancillary Structural Study |
Lisa Chen, MD |
Pharmacology and Drug Treatment |
|
|
Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome |
|
Pharmacology and Drug Treatment, Neurology and Mental Health |
|
|
Allosteric Inhibition of a Family of Proteolytic Enzymes |
Charles Craik, PhD |
Immunology, Pharmacology and Drug Treatment |
|
|
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Phase III Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy vs Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Locally Advanced or Metastatic Non Small-Cell Lung Cancer |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Advanced Non-small Cell Lung Carcinoma |
|
Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Actelion - AC-065A304 Multicenter, open-label, single-group study to assess the tolerability and the safety of the TRANSITion from inhaled tresprostinil to oral selexipag in patients with pulmonary arterial hypertension 20150803 |
|
Cardiovascular Disease, Pharmacology and Drug Treatment |
|
|
Trial of Pirfenidone in CKD, TOP CKD |
Michael Shlipak, MD |
Pharmacology and Drug Treatment |
|
|
Management Sciences for Health Director of Capacity Building and Performance Improvement |
Tina Brock, MS, EdD |
Pharmacology and Drug Treatment, Policy and Standards of Care, Systematic Reviews and Guideline Development, Training and Capacity Building |
|
|
Associate Dean for Global Health and Educational Innovations UCSF School of Pharmacy |
Tina Brock, MS, EdD |
Pharmacology and Drug Treatment, Health Economics and Effectiveness, Access or Barriers to Care, Policy and Standards of Care, Health Systems Strengthening |
|
|
The inverse association between cancer and Alzheimers disease: comparing spurious and causal explanations to illuminate the causes of Alzheimers disease |
Maria Glymour, ScD, MS |
Pharmacology and Drug Treatment, Neurology and Mental Health, Dementia and Cognitive Impairment |
|
|
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection |
Steven Stoltz, MD |
Pharmacology and Drug Treatment |
|
|
Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy & Safety of Pimodivir in Combination With Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection |
Steven Stoltz, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Development and validation for an HPLC-UV multiplex assay for therapeutic drug monitoring of antiretroviral drugs in Uganda |
Allan Buzibye, Bsc |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Pediatric drug dosing in very low resource environments |
|
Malnutrition, Micronutrients, Food Insecurity, Pharmacology and Drug Treatment, Immigration and Migration, Systematic Reviews and Guideline Development |
|
|
Antimalarial drugs in Ugandan populations |
Melissa Conrad, PhD |
HIV/AIDS, Malaria, Drug and Diagnostics Development, Pharmacology and Drug Treatment, Pediatrics |
|
|
he Efficacy of Various Antibiotics at Targeting Wolbachia for the Treatment of Lymphatic Filariasis |
Emma Gunderson, MS |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Pain Management in Clinic & Community |
Kelly Knight, PhD |
Pharmacology and Drug Treatment |
|
|
Kebele Elimination of Trachoma for Ocular Health |
Catherine Oldenburg, ScD, MPH |
Eye Disease and Blindness, Pharmacology and Drug Treatment, Epidemiology and Surveillance |
|
|
Building Evidence for Advancing New Treatment For XDR/XDR-TB (BEAT TUBERCULOSIS) Study |
Patrick Phillips, PhD, MS, MA |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Pharmacology and Drug Treatment |
|
|
Modernization of Phase 3 TB Clinical Trial Endpoints |
Patrick Phillips, PhD, MS, MA |
Tuberculosis, Pharmacology and Drug Treatment, Systematic Reviews and Guideline Development |
|
|
Clinical trials to improve the treatment of drug-sensitive and MDR-TB |
Patrick Phillips, PhD, MS, MA |
Tuberculosis, Immunology, Pharmacology and Drug Treatment |
|
|
PK/PD modeling to optimize prevention in African children |
Erika K. Wallender, MD |
Malaria, Pharmacology and Drug Treatment |
|
|
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged >14 years Presenting with Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC) |
Mohamed Fayed, MD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Pharmacology and Drug Treatment |
|
|